BioSpace News Archive

Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, provided a corporate update, highlighting the progress of key programs.

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced a business update and preliminary, unaudited financial results for the fourth quarter of 2021.

Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, outlined key objectives and anticipated milestones for 2022 and provided an overview of recent progress.

Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, announced its participation in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, provided a clinical development plan for its anti-TIGIT monoclonal antibody, EOS-448, and its A2A receptor antagonist, inupadenant.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the appointment of Michael C. Pine as Chief Corporate Development and Strategy Officer.

BioCryst Pharmaceuticals, Inc. announced preliminary, unaudited ORLADEYO® revenue for the fourth quarter and full year 2021 and provided new guidance for full year 2022 ORLADEYO net revenue and expected peak ORLADEYO sales.

Travere Therapeutics announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2021 to be approximately $55 million.

Anavex Life Sciences Corp. announced positive top-line results from its Phase 1 clinical trial of ANAVEX®3-71, an oral small molecule agonist of both SIGMAR1 and CHRM1 in development for the treatment of neurodegenerative diseases including Frontotemporal Dementia, for which ANAVEX®3-71 has been granted Orphan Drug Designation by the FDA.

Skye Bioscience, Inc., a pharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat diseases with significant unmet need, issued the following letter from Chief Executive Officer and Chair, Punit Dhillon.